Website News and Research

RSS

Aastrom Biosciences prices public offering

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with each unit consisting of one share of the Company's common stock and one warrant to purchase one share of common stock, at a purchase price of $2.25 per unit for an aggregate offering amount of $22.5 million.

10 Dec 2010

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

Behavioral scientist and tobacco-cessation expert, Alexander V. Prokhorov, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center is the recipient of the 2011 American Society of Preventive Oncology (ASPO) Joseph W. Cullen Memorial Award for Excellence in Tobacco Research.

10 Dec 2010

MyHospital website goes live

The public will have access to nationally-consistent performance data for almost 1,000 Australian hospitals online for the first time at the federal government’s MyHospitals website. The website includes information on 922 public and private hospitals around the country and is live at 11am (AEDT) on Friday.

9 Dec 2010

Cardiac Science adds two ECGs to Burdick line

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today adds two electrocardiographs (ECGs) under its Burdick brand, known for its accuracy, reliability, and ease of use. The ECGs, available only in the U.S., deliver built-in, bi-directional communication so customers can connect to leading EMRs.

9 Dec 2010

Study to develop ways to track individual's exposure to traffic pollution

Researchers at King's College London are developing ways of working out a person's individual exposure to traffic pollution when travelling to, from, and around London.

9 Dec 2010

Results of proteomics study performed utilizing plasma samples from ADNI now available

The Foundation for the National Institutes of Health's Biomarkers Consortium announced today that the results of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative are ready to be shared with scientists worldwide for further analysis.

9 Dec 2010

Health2 Resources provides strategic research, analysis for ACCC project

The Association of Community Cancer Centers announced that results of a landmark study of how—and how well—the cancer patient's transition from the hospital inpatient setting to outpatient oncology group is managed. The study, designed to help hospitals and oncology groups improve their transition processes. The study was conducted by the Association of Community Cancer Centers, was conducted by ACCC, with strategic research and analysis provided by Health2 Resources.

9 Dec 2010

Systagenix launches new innovative website

Following the highly successful global launch of the new Corporate Identity, Systagenix has today unveiled its new innovative website - www.systagenix.com.

9 Dec 2010

Dietitians prefer olive oil as food oil of choice

A newly released survey of dietitians, which examines their current perspectives regarding various dietary fats and oils, reveals a strong preference for olive oil as the food oil of choice even for individuals on a diet. Canola oil was the second choice, while other oils—safflower, soybean, peanut, corn and flax—trailed far behind.

9 Dec 2010

Study: Adding community features to online health programs could reduce attrition

In an era when social networking sites and blogs are visited by three quarters of online users, it's only natural that the medical profession would also tap into the power of social media tools.

9 Dec 2010

New website provides guidelines to optimal stroke care

The 2010 Canadian Best Practice Recommendations for Stroke Care emphasize the need to prevent stroke patients from falling through the cracks as they move from the ER to in-hospital care to rehabilitation therapy and back to the community. The recommendations were released today by the Canadian Stroke Network and the Heart and Stroke Foundation of Canada.

8 Dec 2010

Injury prevention for young volleyball athletes

When volleyball was invented 115 years ago in Holyoke, Mass., it was meant to be less rough than basketball, another emerging indoor sport that started four years earlier at a nearby YMCA.

7 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Idis to manage ViroPharma's named patient program

ViroPharma Incorporated and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP). ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to individual patients until the time that approval is sought in local countries.

7 Dec 2010

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Aeterna Zentaris Inc. today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising clinical activity, safety and tolerability in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). The data were presented over the weekend at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.

7 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

Chemo101.com officially launched during ASH meeting

Chemo101.com, a new educational website for cancer patients, made its official launch during the American Society of Hematology meeting this past weekend in Orlando, FL. The brainchild of veteran healthcare consultant to the pharmaceutical industry, Kristin Gustafson, Chemo101 is an innovative and comprehensive new platform that provides those undergoing chemotherapy treatment with the most up-to-date resources and information they need, all in one easy to access place online.

6 Dec 2010

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

6 Dec 2010

KIRN 670AM RADIOIRAN to create new awareness about prostate cancer

KIRN 670AM RADIOIRAN has been serving the Iranian-American/Persian population of Los Angeles for more than a decade. During the past year, John Paley, VP and General Manager of KIRN, organized a series of interactive informational broadcasts about breast and esophageal cancer. Teams of medical experts in these fields thoroughly reviewed signs, treatment, myths and realities about this implacable disease.

4 Dec 2010

Access adds patient experience testimonial video to MuGard website

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.

4 Dec 2010

Website News and Research

Aastrom Biosciences prices public offering

Tobacco-cessation expert receives 2011 ASPO Joseph W. Cullen Memorial Award tobacco research

MyHospital website goes live

Cardiac Science adds two ECGs to Burdick line

Study to develop ways to track individual's exposure to traffic pollution

Results of proteomics study performed utilizing plasma samples from ADNI now available

Health2 Resources provides strategic research, analysis for ACCC project

Systagenix launches new innovative website

Dietitians prefer olive oil as food oil of choice

Study: Adding community features to online health programs could reduce attrition

New website provides guidelines to optimal stroke care

Injury prevention for young volleyball athletes

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Idis to manage ViroPharma's named patient program

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

Chemo101.com officially launched during ASH meeting

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

KIRN 670AM RADIOIRAN to create new awareness about prostate cancer

Access adds patient experience testimonial video to MuGard website

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News